These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
113 related articles for article (PubMed ID: 4044076)
1. Model independent pharmacokinetic study of cis-dichlorodiammineplatinum (II). Dumas M; d'Athis P; de Gislain C; Escousse A; Guerrin J; Autissier N Int J Clin Pharmacol Ther Toxicol; 1985 Aug; 23(8):430-3. PubMed ID: 4044076 [TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic study of Cis-dichlorodiammine platinum II, in children after rapid infusion. Cano JP; Catalin J; Rigault JP; Bues-Charbit M; Placidi M; Raybaud C; Bernard JL Biomedicine; 1981 Dec; 34(3):146-53. PubMed ID: 7199945 [TBL] [Abstract][Full Text] [Related]
3. Kinetics of platinum in cancer patients treated with cisplatin at different doses. Fracasso ME; Apostoli P; Benoni G; Bonetti A; Griso C; Leone R Drugs Exp Clin Res; 1987; 13(6):367-72. PubMed ID: 3652926 [TBL] [Abstract][Full Text] [Related]
4. [Pharmacokinetics of cisplatin and the effect of sodium thiosulfate]. Hayata S; Hitoshi T; Kiyokawa K; Esaki S; Mihashi S; Hirano M Gan To Kagaku Ryoho; 1984 Nov; 11(11):2356-61. PubMed ID: 6541891 [TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic evidence for an enterohepatic circulation in a patient treated with cis-dichlorodiammineplatinum (II). Vermorken JB; van der Vijgh WJ; Pinedo HM Res Commun Chem Pathol Pharmacol; 1980 May; 28(2):319-28. PubMed ID: 7190316 [TBL] [Abstract][Full Text] [Related]
6. [Pharmacokinetics of cis-dichlorodiammineplatinum (II)]. Horiuchi M; Inuyama Y; Kohno N; Mashino S; Fujii M Gan To Kagaku Ryoho; 1982 Apr; 9(4):632-7. PubMed ID: 6892197 [TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of non-protein-bound platinum species following administration of cis-dichlorodiammineplatinum(II). Belt RJ; Himmelstein KJ; Patton TF; Bannister SJ; Sternson LA; Repta AJ Cancer Treat Rep; 1979; 63(9-10):1515-21. PubMed ID: 498151 [TBL] [Abstract][Full Text] [Related]
8. Influence of frusemide on cis-dichlorodiammineplatinum (II) pharmaco-kinetics. Dumas M; d'Athis P; de Gislain C; Lautissier JL; Autissier N; Escousse A; Guerrin J Eur J Drug Metab Pharmacokinet; 1987; 12(3):203-6. PubMed ID: 3436343 [TBL] [Abstract][Full Text] [Related]
9. cis-Amminedichloro(2-methylpyridine) platinum(II) (AMD473), a novel sterically hindered platinum complex: in vivo activity, toxicology, and pharmacokinetics in mice. Raynaud FI; Boxall FE; Goddard PM; Valenti M; Jones M; Murrer BA; Abrams M; Kelland LR Clin Cancer Res; 1997 Nov; 3(11):2063-74. PubMed ID: 9815598 [TBL] [Abstract][Full Text] [Related]
10. Distribution and disposition of platinum following intravenous administration of cis-diamminedichloroplatinum(II) (NSC 119875) to dogs. Litterst CL; Gram TE; Dedrick RL; Leroy AF; Guarino AM Cancer Res; 1976 Jul; 36(7 PT 1):2340-4. PubMed ID: 1277140 [TBL] [Abstract][Full Text] [Related]
11. Potential effects of edema on the pharmacokinetics of platinum in patients treated with cis-dichlorodiammine platinum (II). Buice RG; Soloway MS Res Commun Chem Pathol Pharmacol; 1980 Dec; 30(3):447-57. PubMed ID: 7196063 [TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of platinum after oral or intravenous cisplatin: a phase 1 study in 32 adult patients. Urien S; Brain E; Bugat R; Pivot X; Lochon I; Van ML; Vauzelle F; Lokiec F Cancer Chemother Pharmacol; 2005 Jan; 55(1):55-60. PubMed ID: 15258698 [TBL] [Abstract][Full Text] [Related]
13. [Pharmacokinetics of cis-dichlorodiammine platinum (II) in patients undergoing hemodialysis]. Miyakawa M; Sugimoto K; Ohe Y; Masuoka H; Miyahara T Gan To Kagaku Ryoho; 1987 Aug; 14(8):2491-5. PubMed ID: 3619461 [TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and dosage reduction of cis-diammine(1,1-cyclobutanedicarboxylato)platinum in patients with impaired renal function. Egorin MJ; Van Echo DA; Tipping SJ; Olman EA; Whitacre MY; Thompson BW; Aisner J Cancer Res; 1984 Nov; 44(11):5432-8. PubMed ID: 6386150 [TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of cis-diamminedichloroplatinum(II) after administration in hypertonic saline. Bajorin DF; Bosl GJ; Alcock NW; Niedzwiecki D; Gallina E; Shurgot B Cancer Res; 1986 Nov; 46(11):5969-72. PubMed ID: 3756934 [TBL] [Abstract][Full Text] [Related]
16. Application of cisplatin as intraoperative hyperthermic peritoneal lavage (IHPL) in patients with locally advanced gastric cancer: analysis of pharmacokinetics and of nephrotoxicity. Kern W; Braess J; Kotschofsky M; Samel S; Becker H; Hiddemann W; Schleyer E Anticancer Res; 2002; 22(5):3099-102. PubMed ID: 12530050 [TBL] [Abstract][Full Text] [Related]
17. Phase I and pharmacokinetic study of ormaplatin (tetraplatin, NSC 363812) administered on a day 1 and day 8 schedule. Schilder RJ; LaCreta FP; Perez RP; Johnson SW; Brennan JM; Rogatko A; Nash S; McAleer C; Hamilton TC; Roby D Cancer Res; 1994 Feb; 54(3):709-17. PubMed ID: 8306332 [TBL] [Abstract][Full Text] [Related]
18. Clinical pharmacology of intraarterial cis-diamminedichloroplatinum(II). Stewart DJ; Benjamin RS; Zimmerman S; Caprioli RM; Wallace S; Chuang V; Calvo D; Samuels M; Bonura J; Loo TL Cancer Res; 1983 Feb; 43(2):917-20. PubMed ID: 6681533 [TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of cis-diammine-1,1-cyclobutane dicarboxylate platinum(II) in patients with normal and impaired renal function. Harland SJ; Newell DR; Siddik ZH; Chadwick R; Calvert AH; Harrap KR Cancer Res; 1984 Apr; 44(4):1693-7. PubMed ID: 6367971 [TBL] [Abstract][Full Text] [Related]